The Role of Native T1 and T2 Mapping Times in Identifying PD-L1 Expression and the Histological Subtype of NSCLCs.
T1 mapping
T2 mapping
lung MRI
non-small cell lung cancer (NSCLC)
programmed death-ligand 1 (PD-L1)
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
20 Jun 2023
20 Jun 2023
Historique:
received:
06
05
2023
revised:
08
06
2023
accepted:
16
06
2023
medline:
28
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
We investigated the association of T1/T2 mapping values with programmed death-ligand 1 protein (PD-L1) expression in lung cancer and their potential in distinguishing between different histological subtypes of non-small cell lung cancers (NSCLCs). Thirty-five patients diagnosed with stage III NSCLC from April 2021 to December 2022 were included. Conventional MRI sequences were acquired with a 1.5 T system. Mean T1 and T2 mapping values were computed for six manually traced ROIs on different areas of the tumor. Data were analyzed through RStudio. Correlation between T1/T2 mapping values and PD-L1 expression was studied with a Wilcoxon-Mann-Whitney test. A Kruskal-Wallis test with a post-hoc Dunn test was used to study the correlation between T1/T2 mapping values and the histological subtypes: squamocellular carcinoma (SCC), adenocarcinoma (ADK), and poorly differentiated NSCLC (PD). There was no statistically significant correlation between T1/T2 mapping values and PD-L1 expression in NSCLC. We found statistically significant differences in T1 mapping values between ADK and SCC for the periphery ROI (
Identifiants
pubmed: 37370861
pii: cancers15123252
doi: 10.3390/cancers15123252
pmc: PMC10296658
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Fondazione IRCCS Policlinico San Matteo
ID : 20190049910
Références
JACC Cardiovasc Imaging. 2013 Jul;6(7):806-22
pubmed: 23845576
Front Oncol. 2017 Aug 28;7:193
pubmed: 28894699
Proc Natl Acad Sci U S A. 2017 Jul 11;114(28):E5625-E5634
pubmed: 28652369
Nat Commun. 2017 Nov 23;8(1):1734
pubmed: 29170406
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Cancers (Basel). 2022 Nov 16;14(22):
pubmed: 36428726
Acta Radiol. 2019 Sep;60(9):1181-1189
pubmed: 30621443
J Thorac Imaging. 2014 May;29(3):147-54
pubmed: 24576837
J Thorac Imaging. 2013 May;28(3):138-50
pubmed: 23549390
JACC Cardiovasc Imaging. 2018 Jan;11(1):48-59
pubmed: 28624408
Lung Cancer. 2015 Feb;87(2):193-200
pubmed: 25564398
J Thorac Dis. 2020 May;12(5):2517-2528
pubmed: 32642159
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nat Rev Cancer. 2021 Apr;21(4):217-238
pubmed: 33589810
J Magn Reson Imaging. 2012 Oct;36(4):805-24
pubmed: 22987758
Transl Lung Cancer Res. 2016 Jun;5(3):288-300
pubmed: 27413711
Pol J Radiol. 2019 Dec 18;84:e549-e564
pubmed: 32082454
IEEE Trans Radiat Plasma Med Sci. 2019 Jul;3(4):509-515
pubmed: 32066996
JACC Cardiovasc Imaging. 2013 Apr;6(4):488-97
pubmed: 23498672
Clin Med Insights Cardiol. 2014 Dec 01;8(Suppl 4):1-11
pubmed: 25525401
J Thorac Dis. 2022 Feb;14(2):443-454
pubmed: 35280462
Cancer Imaging. 2020 Dec 14;20(1):88
pubmed: 33317609
COPD. 2016;13(2):153-9
pubmed: 26488310
Eur J Radiol. 2014 Nov;83(11):2093-101
pubmed: 25176287
JACC Cardiovasc Imaging. 2012 Jun;5(6):596-603
pubmed: 22698528
JACC Cardiovasc Imaging. 2016 Jan;9(1):67-81
pubmed: 26762877
Front Oncol. 2020 Sep 11;10:1766
pubmed: 33014869
BMC Med Imaging. 2023 Jan 4;23(1):1
pubmed: 36600192
J Magn Reson Imaging. 2021 Nov;54(5):1529-1540
pubmed: 34291852